1 to 9 of 12 results

Novartis finally gets Alcon; vildagliptin now available for elderly type 2 diabetics in UK


In what looks to be the last hurdle for Swiss drug major Novartis (NOVN: VX) to take full control of…

AlconDiabetesMergers & AcquisitionsNovartisOphthalmicsPharmaceuticalRegulationvildagliptin

Novartis finally reaches agreement with Alcon’s minority shareholders for full control


Ending a long struggle to gain 100% control of eye care specialist Alcon (NYSE: ACL), Swiss drug major…

AlconMergers & AcquisitionsNovartisOpthalmicsPharmaceutical

Novartis in $422.5 million settlement over US illegal marketing; cites Swiss law expert on Alcon IDC’s legal position in proposed merger


Swiss drug major Novartis (NOVN: VX) says its US subsidiary, Novartis Pharmaceuticals Corp (NPC), has…

AlconLegalMergers & AcquisitionsNovartisOphthalmicsPharmaceutical

Bausch & Lomb moves to acquire Miochol-E from Novartis as required by US competition authority


In order to comply with US anti-trust requirements imposed by the Federal Trade Commission to complete…

AlconBausch & LombLegalMergers & AcquisitionsMiochol-ENovartisOphthalmicsPharmaceutical

UK's NICE gives final 'no' to NHS use of Novartis cancer drug Glivec; Novartis now holds 77% of Alcon


In another negative decision on the use of cancer drugs on the National Health Service in England and…

AlconGleevecGlivecMergers & AcquisitionsNovartisOncologyPharmaceuticalRegulation

Novartis buy of Alcon moves forward, but USA and China competition authorities call for divestments


Swiss drug major Novartis will be required to sell an injectable eye care drug used in cataract surgery…

AlconMergers & AcquisitionsNovartisOphthalmicsPharmaceutical

Novartis must get Alcon IDC approval for buyout, says Swiss corporate governance expert


Fuelling further delay in Swiss drug major Novartis’ plans to buy 100% of ophthalmic drugs and eye…

AlconMergers & AcquisitionsNovartisOphthalmicsPharmaceutical

Alcon Independent Director Committee says Novartis’ offer still grossly inadequate, especially given Alcon’s strong earnings


The Independent Director Committee of Switzerland-based ophthalmics group Alcon yesterday reiterated…

AlconMergers & AcquisitionsNovartisOphthalmicsPharmaceutical

1 to 9 of 12 results



Back to top